---
title: "Congenital syphilis risk similar for 6–8 vs 9‑day benzathine penicillin G dosing intervals in preg"
id: "medrxiv-11-congenital-syphilis-outcomes-by-penicillin-dosing-intervals-among-women-with"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-congenital-syphilis-outcomes-by-penicillin-dosing-intervals-among-women-with"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.03.26361028v1?rss=1"
published_at: "2026-09-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Congenital syphilis risk similar for 6–8 vs 9‑day benzathine penicillin G dosing intervals in preg
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-congenital-syphilis-outcomes-by-penicillin-dosing-intervals-among-women-with
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.03.26361028v1?rss=1)
- **Published At:** 2026-09-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study examined outcomes of **congenital syphilis** among pregnant people with late latent or latent of unknown duration syphilis in eight U.S. jurisdictions during 2018–2023. - Current guidance recommends three doses of **benzathine penicillin G** administered each 9 days or fewer apart for this indication. - Authors compared outcomes by penicillin **dosing intervals**, specifically a 9-day interval versus 6–8 day intervals between doses. - The analysis found no significant difference in the risk of congenital syphilis between the 9-day interval group and the 6–8 day interval group. - The work was conducted by CDC-affiliated investigators and collaborators from multiple state and local health departments and treated as public health surveillance; it was exempt from IRB review per CDC procedures. - Data supporting the analysis are subject to CDC confidentiality protections under the Public Health Service Act; access requests are handled case by case via the CDC setnet contact. - Funding and support were provided through CDC cooperative agreements and contractual mechanisms; investigators declared no competing interests. - The preprint was posted on medRxiv; the article includes author and institutional affiliations and notes adherence to relevant ethical and reporting guidelines.
## Clinical Analysis & Structured Key Points
Congenital syphilis outcomes by penicillin dosing intervals among women with late latent or latent of unknown duration syphilis during pregnancy in eight U.S. jurisdictions: 2018-2023 | medRxiv Skip to main content Congenital syphilis outcomes by penicillin dosing intervals among women with late latent or latent of unknown duration syphilis during pregnancy in eight U.S. jurisdictions: 2018-2023 Ellen Martinson , Elizabeth L. Lewis , Suzy Newton , Jeffrey M. Carlson , Kathryn Miele , Kevin P. O'Callaghan , Breanne Anderson , Tia Falzarano , Toby R. Levin , Mallory Jayroe , Caroline M. Johnson , Nicole D. Longcore , Adam Berryhill , Teri' Willabus , Kate R. Woodworth , Van T. Tong doi: https://doi.org/10.64898/2026.09.03.26361028 Ellen Martinson 1 Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: tgx8{at}cdc.gov Elizabeth L. Lewis 1 Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Suzy Newton 1 Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jeffrey M. Carlson 1 Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kathryn Miele 2 Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kevin P. O'Callaghan 2 Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Breanne Anderson 3 Arizona Department of Health Services, Phoenix, AZ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tia Falzarano 4 Michigan Department of Health and Human Services, Detroit, MI; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Toby R. Levin 5 New Jersey Department of Health, Trenton, NJ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mallory Jayroe 6 Arkansas Department of Health, Little Rock, AR; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Caroline M. Johnson 7 Washington State Department of Health, Tumwater, WA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nicole D. Longcore 8 New York State Department of Health, Albany, NY; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Adam Berryhill 9 Maricopa County Department of Public Health, Phoenix, AZ; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Teri' Willabus 10 Georgia Department of Public Health, Atlanta, GA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kate R. Woodworth 1 Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Van T. Tong 1 Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Pregnant women with late latent or latent of unknown duration syphilis are recommended to receive three doses of benzathine penicillin G each 9 or fewer days apart; data on interval variations are limited. We found no significant difference in risk of congenital syphilis between 9-day and 6-8 day dosing intervals. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This activity was reviewed by CDC and conducted consistent with applicable federal law and policy (45 C.F.R. part 46.102(l)(2), 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a). It was deemed public health surveillance and exempt from IRB. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability These data are collected under relevant provisions of the Public Health Service Act and are protected at CDC by an Assurance of Confidentiality (Section 308(d) of the Public Health Service Act, 42 U.S.C. 242 m(d))(https://www.cdc.gov/od/science/integrity/confidentiality/), which prohibits use or disclosure of any identifiable or potentially identifiable information collected under the Assurance for purposes other than those set out in the Assurance. Requests for access will be considered on a case by case basis, and inquiries should be directed to setnet{at}cdc.gov. Funder Information Declared Centers for Disease Control and Prevention, https://ror.org/042twtr12 , This study was performed as regular work of the Centers for Disease Control and Prevention (CDC) and is supported by the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreements (CDC-RFA-CK19-1904 and CDC-RFA-CK24-0002), Division of Birth Defects and Infant Disorders Cooperative Agreement (CDC-RFA-DD-23-0003), and through contractual mechanisms, including the Local Health Department Initiative to Chickasaw Health Consulting (200-2021-F-12655). Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Back to top Previous Next Posted September 07, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Congenital syphilis outcomes by penicillin dosing intervals among women with late latent or latent of unknown duration syphilis during pregnancy in eight U.S. jurisdictions: 2018-2023 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Congenital syphilis outcomes by penicillin dosing intervals among women with late latent or latent of unknown duration syphilis during pregnancy in eight U.S. jurisdictions: 2018-2023 Ellen Martinson , Elizabeth L. Lewis , Suzy Newton , Jeffrey M. Carlson , Kathryn Miele , Kevin P. O'Callaghan , Breanne Anderson , Tia Falzarano , Toby R. Levin , Mallory Jayroe , Caroline M. Johnson , Nicole D. Longcore , Adam Berryhill , Teri' Willabus , Kate R. Woodworth , Van T. Tong medRxiv 2026.09.03.26361028; doi: https://doi.org/10.64898/2026.09.03.26361028 Share This Article: Copy Citation Tools Congenital syphilis outcomes by penicillin dosing intervals among women with late latent or latent of unknown duration syphilis during pregnancy in eight U.S. jurisdictions: 2018-2023 Ellen Martinson , Elizabeth L. Lewis , Suzy Newton , Jeffrey M. Carlson , Kathryn Miele , Kevin P. O'Callaghan , Breanne Anderson , Tia Falzarano , Toby R. Levin , Mallory Jayroe , Caroline M. Johnson , Nicole D. Longcore , Adam Berryhill , Teri' Willabus , Kate R. Woodworth , Van T. Tong medRxiv 2026.09.03.26361028; doi: https://doi.org/10.64898/2026.09.03.26361028 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Epidemiology Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (897) Anesthesia (328) Cardiovascular Medicine (4781) Dentistry and Oral Medicine (476) Dermatology (411) Emergency Medicine (646) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1617) Epidemiology (15867) Forensic Medicine (32) Gastroenterology (1196) Genetic and Genomic Medicine (7006) Geriatric Medicine (728) Health Economics (1060) Health Informatics (5007) Health Policy (1429) Health Systems and Quality Improvement (1747) Hematology (583) HIV/AIDS (1338) Infectious Diseases (except HIV/AIDS) (16258) Intensive Care and Critical Care Medicine (1164) Medical Education (665) Medical Ethics (151) Nephrology (721) Neurology (7216) Nursing (366) Nutrition (1074) Obstetrics and Gynecology (1234) Occupational and Environmental Health (1002) Oncology (3584) Ophthalmology (1044) Orthopedics (395) Otolaryngology (449) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1784) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5851) Public and Global Health (9719) Radiology and Imaging (2399) Rehabilitation Medicine and Physical Therapy (1438) Respiratory Medicine (1245) Rheumatology (636) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (772) Toxicology (107) Transplantation (303) Urology (288)
## Related Clinical Research

- [IeDEA 2026 Site Assessment: Protocol for a Cross-Sectional Survey of HIV Clinics and Service Deliv](https://medichelpline.com/clinical-feed/medrxiv-12-documenting-hiv-service-delivery-and-adoption-of-evidence-based-practices-in.md)
- [Lyme disease incidence in England 2013–2024: updated multiplication factor and case trends](https://medichelpline.com/clinical-feed/medrxiv-13-trends-in-lyme-disease-incidence-in-england-2013-to-2024.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Kennedy renews attacks on vaccines at Children’s Health Defense conference](https://medichelpline.com/clinical-feed/stat-news-1-kennedy-renews-attacks-on-vaccines-at-children-s-health-defense-conference.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.